Arcus Biosciences to Host Investor Event Featuring New Data for Casdatifan as a Treatment for Kidney Cancer Across Multiple Lines of Therapy

Arcus Biosciences to Host Investor Event Featuring New Data for Casdatifan as a Treatment for Kidney Cancer Across Multiple Lines of Therapy

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of cancer and inflammatory diseases, announced today that it will host an in-person investor event with a live webcast on Tuesday, October 20, 2026, beginning at 8:30 AM ET, in New York City.